• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism.

作者信息

Sciascia Savino, Breen Karen, Hunt Beverley J

出版信息

Blood Coagul Fibrinolysis. 2015 Jun;26(4):476-7. doi: 10.1097/MBC.0000000000000247.

DOI:10.1097/MBC.0000000000000247
PMID:25923780
Abstract
摘要

相似文献

1
Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism.利伐沙班在抗磷脂综合征和既往有静脉血栓栓塞症患者中的应用。
Blood Coagul Fibrinolysis. 2015 Jun;26(4):476-7. doi: 10.1097/MBC.0000000000000247.
2
After failure with acenocoumarol, rivaroxaban in antiphospholipid syndrome: A report of 2 cases.醋硝香豆素治疗失败后，利伐沙班用于抗磷脂综合征：2例报告
Reumatol Clin (Engl Ed). 2019 Sep-Oct;15(5):e33-e35. doi: 10.1016/j.reuma.2017.04.010. Epub 2017 May 22.
3
Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism.利伐沙班与华法林相比可限制抗磷脂综合征伴静脉血栓栓塞患者的补体激活。
J Thromb Haemost. 2016 Nov;14(11):2177-2186. doi: 10.1111/jth.13475. Epub 2016 Sep 30.
4
Cerebral Venous Thromboembolism in Antiphospholipid Syndrome Successfully Treated with the Combined Use of an Anti-Xa Inhibitor and Corticosteroid.抗磷脂综合征合并脑静脉血栓形成经抗Xa因子抑制剂与皮质类固醇联合治疗成功治愈
Intern Med. 2015;54(23):3051-6. doi: 10.2169/internalmedicine.54.5045. Epub 2015 Dec 1.
5
[Not Available].[无可用内容]。
Hamostaseologie. 2019 Aug;39(3):298-300. doi: 10.1055/s-0039-1694789. Epub 2019 Aug 12.
6
Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome.利伐沙班与维生素K拮抗剂治疗抗磷脂综合征的比较
Ann Intern Med. 2019 Nov 19;171(10). doi: 10.7326/P19-0013. Epub 2019 Oct 15.
7
Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial.利伐沙班与华法林在抗磷脂综合征高危患者中的疗效和安全性：抗磷脂综合征利伐沙班试验（TRAPS）的原理与设计
Lupus. 2016 Mar;25(3):301-6. doi: 10.1177/0961203315611495. Epub 2015 Oct 13.
8
Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.利伐沙班用于抗磷脂综合征（RAPS）的方案：一项关于利伐沙班与华法林对比治疗血栓形成性抗磷脂综合征患者（无论是否合并系统性红斑狼疮）的前瞻性、随机对照II/III期临床试验。
Lupus. 2015 Sep;24(10):1087-94. doi: 10.1177/0961203315581207. Epub 2015 May 4.
9
The use of rivaroxaban in patients with antiphospholipid syndrome: A series of 12 cases.利伐沙班在抗磷脂综合征患者中的应用：12例病例系列
Thromb Res. 2015 May;135(5):1035-6. doi: 10.1016/j.thromres.2015.01.028. Epub 2015 Feb 2.
10
Venous thromboembolism in adults: summary of updated NICE guidance on diagnosis, management, and thrombophilia testing.成人静脉血栓栓塞症：英国国家卫生与临床优化研究所（NICE）关于诊断、管理及易栓症检测的最新指南总结
BMJ. 2020 May 19;369:m1565. doi: 10.1136/bmj.m1565.

引用本文的文献

1
Efficacy and safety of direct oral anticoagulants compared with warfarin in antiphospholipid syndrome. Results of a multicenter retrospective cohort study.直接口服抗凝剂与华法林相比在抗磷脂综合征中的疗效和安全性。一项多中心回顾性队列研究的结果。
Res Pract Thromb Haemost. 2025 Apr 17;9(4):102856. doi: 10.1016/j.rpth.2025.102856. eCollection 2025 May.
2
Clinical Management of Thrombotic Antiphospholipid Syndrome.血栓性抗磷脂综合征的临床管理
J Clin Med. 2022 Jan 29;11(3):735. doi: 10.3390/jcm11030735.
3
Direct oral anticoagulants-Remove versus Taipan snake venom time for detection of a lupus anticoagulant in patients taking oral direct factor Xa inhibitors.
直接口服抗凝剂——在服用口服直接因子Xa抑制剂的患者中，用于检测狼疮抗凝物的稀释蝰蛇毒时间与蝰蛇毒时间的比较
Res Pract Thromb Haemost. 2022 Jan 23;6(1):e12648. doi: 10.1002/rth2.12648. eCollection 2022 Jan.
4
Role of Direct Oral Anticoagulation Agents as Thromboprophylaxis in Antiphospholipid Syndrome.直接口服抗凝剂在抗磷脂综合征血栓预防中的作用。
Cureus. 2021 Oct 24;13(10):e19009. doi: 10.7759/cureus.19009. eCollection 2021 Oct.
5
Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines.抗磷脂综合征患者直接口服抗凝剂的应用：国际指南的系统评价与比较
Front Cardiovasc Med. 2021 Aug 3;8:715878. doi: 10.3389/fcvm.2021.715878. eCollection 2021.
6
Would you use novel oral anticoagulants (NOACs) for thromboprophylaxis in patients with an underlying hypercoagulable state? A literature review through a case report.对于存在潜在高凝状态的患者，您是否会使用新型口服抗凝药物（NOACs）进行血栓预防？通过病例报告进行文献复习。
BMJ Case Rep. 2020 Oct 30;13(10):e237238. doi: 10.1136/bcr-2020-237238.
7
Comparison of the Therapeutic Effects of Rivaroxaban Versus Warfarin in Antiphospholipid Syndrome: A Systematic Review.利伐沙班与华法林治疗抗磷脂综合征的疗效比较：一项系统评价
Arch Rheumatol. 2019 Dec 12;35(1):107-116. doi: 10.5606/ArchRheumatol.2020.7375. eCollection 2020 Mar.
8
Current Controversies in Lupus Anticoagulant Detection.狼疮抗凝物检测中的当前争议
Antibodies (Basel). 2016 Dec 2;5(4):22. doi: 10.3390/antib5040022.
9
Anticoagulating patients with high-risk acquired thrombophilias.抗凝治疗伴有高危获得性易栓症的患者。
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):439-449. doi: 10.1182/asheducation-2018.1.439.
10
[Not Available].[无可用内容]
J Vasc Bras. 2017 Apr-Jun;16(2):140-149. doi: 10.1590/1677-5449.011416.